Results 181 to 190 of about 92,971 (266)

Spectrum of Movement Disorders in Hematological Malignancies: A Comprehensive Systematic Review of Clinical Phenotypes, Mechanisms, and Outcomes. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Garg RK, Jain A, Karoli R, Pandey S, Paliwal V, Suresh V, Singhal S.   +6 more
europepmc   +1 more source

Hairy Cell Leukemia With Aberrant CD5 and CD23 Expression: A Case Report and a Brief Literature Review. [PDF]

Cureus
Alameddine Z, Hamadi R, Attia H, Zhonghua L, Levy R.   +4 more
europepmc   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Po‐Wei Liao, Bor‐Sheng Ko, Yu‐Chen Su, Wei‐Ting Chao, Chieh‐Lin Jerry Teng   +4 more
wiley   +1 more source

Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry. [PDF]

Cureus
Kundu A, Giri S, Basu A.
europepmc   +1 more source

Primary Extramedullary Acute Promyelocytic Leukemia Presenting as Cauda Equina Syndrome: A Rare Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT APL presenting as an extramedullary mass is exceedingly rare. Here, we describe extramedullary APL causing cauda equina syndrome, underscoring the diagnostic challenges associated with an atypical presentation, highlighting the complexity of distinguishing extramedullary APL from other conditions, and discussing the stepwise approach to ...
Amir Ali, Marc Ringor, Arbab Khalid, Diana Garcia, Ravishankar Konchada, Ramalingam Ratnasabapathy, Yuna Chae, Arman Melikyan, George Yaghmour   +8 more
wiley   +1 more source

Unusual Nasopharyngeal Localization of Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Cureus
Fadi M, Anajar S, Chahdi H, Lahlou FA, Bouanani N.   +4 more
europepmc   +1 more source

Methotrexate Toxicity in a Patient With Renal Failure Despite a Normal Methotrexate Concentration: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Methotrexate (MTX) is a folate antagonist widely used as a disease‐modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), as well as in several malignancies and autoimmune disorders. Although low‐dose MTX (5–20 mg/week) is generally considered safe, it has a narrow therapeutic index, and toxicity can occur even at therapeutic doses,
Fatemeh Afra, Mahshad Ghoddusi, Mahsa Mottahedi, Maryam Albaji, Samira Kafan, Roya Saedpanah, Amir Shokri, Elham Nazar   +7 more
wiley   +1 more source

A microRNA expression signature in infant t(4;11) KMT2A::AFF1+ BCP-ALL uncovers novel therapeutic targets. [PDF]

Hemasphere
Malouf C, Duguid A, Vrenken KS, Leah T, Medhi R, Camiolo G, Nitsche L, Jakobczyk H, Kotecha RS, Anderson RA, Barrett NA, Smith OP, Stam RW, Ottersbach K.   +13 more
europepmc   +1 more source

SIRT1: Protean roles at the nexus of health, disease, and therapeutics

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
SIRT1 serves as a central regulator linking metabolism, stress responses, and disease. It influences diverse processes, including transcriptional and posttranscriptional gene expression and protein activity, inflammation, mitochondrial function, and cell survival, through the deacetylation of multiple protein targets. While SIRT1 often plays protective
Brahim Chaqour
wiley   +1 more source

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report. [PDF]

SAGE Open Med Case Rep
Benallaoua K, Lacoeuilhe P, Gendrot B, Muhammad S, Fouquet G.   +4 more
europepmc   +1 more source